| Company Name | Astellas Pharma Taiwan |
|---|---|
| Protocol Number | HAURO-1201-TW |
| Title of Study | An open-label, prospective interventional study of the tolerability and efficacy of oral Harnalidge® OCAS®(Tamsulosin) 0.4 mg in patients who are unsatisfied with the treatment of Tamsulosin 0.2 mg 一項開放式、前瞻性介入試驗，評估對Tamsulosin 0.2 mg 治療不滿意的患者，口服Harnalidge® OCAS® (Tamsulosin) 0.4 mg 之耐受性及療效 |
| Primary Objective | To assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) 針對台灣良性攝護腺肥大造成下泌尿道症狀，接受Tamsulosin 0.2 mg 治療後不滿意之患者，評估HarnalidgeOCAS (Tamsulosin) 0.4 mg 之耐受性及療效 |
| Number of Sites | 1 |
| Period of Study | From：01-Feb-2014 to：31-Dec-2014 |
| Number of Patients | 100人 |
| IRB Approval Date | 18-Sep-2013 |
| Publication Plan / Date | 2016 |
